Overview

Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)

Status:
Completed

Trial end date:
2020-07-13

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the safety and tolerability of study drug(s) in participants with nonalcoholic steatohepatitis (NASH).

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences

Collaborator:

Novo Nordisk A/S

Treatments:

Firsocostat